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Abstract
Cutaneous T cell lymphoma (CTCL) is a rare, incurable, chronic disease accounting for
approximately 3% of non-Hodgkin’s lymphoma diagnoses every year. Patients with CTCL have
skin lesions that can vary in severity putting patients at risk for developing symptoms that may
impair their quality of life (QOL). The disease burden can lead to increased depressive
symptoms, fatigue distress, and anxiety that the disease may be worsening. Seventy-five
participants agreed to take part in an exploratory, prospective study to evaluate depressive
symptoms, anxiety, fatigue distress, and spirituality as predictors of QOL in CTCL patients.
Demographic variables including stage of disease, ethnicity, age, gender, marital status, level of
education, and time since diagnosis, were also included in the analyses to assess for
relationships. Bivariate correlations, t-tests, and regression analyses were conducted to assess
for relationships among the predictor variables and QOL. The analyses revealed that the
proposed model explained 64% of the variance, and depressive symptoms (t= -2.4, p= 0.020)
and stage of disease (t= -3.0, p= 0.004) significantly predicted the QOL of CTCL patients.
Evaluating for predictors that influence the QOL helps us to better understand the needs of the
patients afflicted with CTCL. The importance of studying the QOL of the CTCL patients lies in
the fact that nurses can assist in helping patients alleviate some of the symptoms they
experience, thereby improving their QOL. Further study is warranted in developing
interventions to assist in the preservation of QOL.
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Chapter I: Introduction
Cutaneous T cell lymphoma (CTCL) is a malignancy characterized by the presence of a
clonal T lymphocyte population in the skin and affects the largest, most visible organ that we
possess, the skin. CTCL may initially present with patch or plaque lesions on the skin, which
tends to resemble psoriatic lesions. In the United States, approximately 16,000 to 20,000
people are currently living with a diagnosis of CTCL. In addition, approximately 1200 new cases
of this disease are diagnosed each year (Demierre, Gan, Jones, & Miller, 2006; Sampogna, et
al, 2009). Like psoriasis, CTCL is chronic, indolent in nature, and has complex pathophysiology
involving the manifestations of a dysfunctional immune system primarily affecting the skin
(Kimball, Jacobson, Weiss, Vreeland, & Wu, 2005; Pereira, Brito, & Smith, 2011). This disease
causes itchy, painful, flakey, and erythematous skin that can significantly impact the quality of
life in affected patients. It has also been known to have a higher incidence in men than women
and is typically diagnosed in older patients (Kim & Hoppe, 1999). Patients with a diagnosis of
CTCL are part of a small population that suffers from a chronic, incurable disease.
Clinical manifestations may imitate indolent, non-malignant conditions; therefore,
obtaining a biopsy is important in confirming the diagnosis of CTCL. The specimen undergoes
morphologic and immunohistochemical evaluation. The observed infiltrate consists of both CD4
positive (+) and CD8 positive (+) T cells, more specifically clonal CD4+ CD45RO positive (+)
skin homing cells (Demierre et al, 2006; Wong, Mishra, Hake, & Porcu, 2011). The diagnosis of
CTCL is further supported by an increased ratio of CD4+ to CD8+ T cells, TCR clonality, and
loss of surface antigens such as clusters of differentiation 5 (CD5), CD7, and CD26.
Morphological features such as exocytosis, epidermotropism, and Pautrier’s microabscess may
1

also be present (Wong et al, 2011). Microscopic and immunophenotypic evaluation of Pautrier’s
microabscess demonstrate that they are intraepidermal collections of malignant T lymphocytes
that are in close proximity to dendritic cells also known as Langerhan’s cells. From this
information came the hypothesis that cytokines released from the Langerhan’s cells recruit
malignant CD4+ cells to the epidermis. This cross talk may also be important for disease
progression (Wong et al, 2011).
Histopathology reveals infiltration of reactive CD8+ and malignant CD4+ T cells, with a
dominance of T helper cell type 1 (TH1) cytokine patterns in early stages, with a gradual shift
to the predominance of CD4+ T cells and T helper cell type 2 (TH2) skewing in advanced stages
of CTCL (Wong et al, 2011). This suggests that the loss of CD8+ mediated immune response
may parallel the progression of disease.
Staging of disease is imperative for determining treatment and prognosis. Complete
physical examination to assess the percentage of body surface area that is involved is
imperative. Recommendations also include laboratory studies, viral studies to include EpsteinBarr Virus (EBV) and cytomegalovirus (CMV) by Polymerase Chain Reaction (PCR), hepatitis
panel, Human Immunodeficiency Virus (HIV) 1 & 2, and human T lymphocyte virus (HTLV) 1 &
2. Positive Emission Topography (PET) and Computed Topography (CT) scans upon initial
evaluation will show the presence or absence of lymphadenopathy and/ or organomegaly and
should be obtained. Bone marrow biopsy should be performed if systemic disease is suspected
(NCCN, 2012). Staging has been presented by the National Comprehensive Cancer Network
(Tables 1 & 2).
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Table 1.
TNMB

TNMB Classification and staging of Cutaneous T Cell Lymphoma

Skin
T1

Limited patches, papules and/or plaques covering <10% BSA

T2

Patches, papules and/or plaques covering >10% BSA

T3

One or more tumors (>1 cm in diameter)

T4

Confluence of erythema >80% BSA

N0

No clinically abnormal peripheral lymph nodes; biopsy not required

N1

Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1

N2

Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2

N3

Clinically abnormal peripheral lymph nodes; histopathology Dutch or 3-4

NX

Clinically abnormal peripheral lymph nodes; no histologic confirmation

Node

Visceral
M0

No visceral organ involvement

M1

Visceral involvement( must have pathology confirmation and organ should be specified)

Blood
B0

Absence of significant blood involvement: <5% of peripheral blood lymphocytes are
atypical (Sezary) cells.

B1
Low blood tumor burden: >5% of peripheral blood lymphocytes are atypical (Sezary) cells
but does not meet the criteria of B2
B2

High blood tumor burden: >1000mcl Sezary cell

3

Table 2. Staging for Cutaneous T-cell Lymphoma.
T

N

M

B

IA

1

0

0

0, 1

IB

2

0

0

0, 1

IIA

1-2

1, 2

0

0, 1

IIB

3

0-2

0

0, 1

IIIA

4

0-2

0

0

IIIB

4

0-2

0

1

IVA

1-4

0-2

0

2

IVA

1-4

3

0

0-2

IVB

1-4

0-3

1

0-2

Cytokine profiles performed on lesional skin from patients representing all stages of
disease have provided clues to the changes in the microenvironment during progression of
CTCL (Wong et al, 2011). Normal to increased expression of interleukin-2 (IL-2), interleukin-12
(IL-12), and interferon gamma (IFNG), a normal T helper cell type 1 (TH1) cytokine pattern, is
observed in early stage CTCL. Decreased IL-2, IL-12, and IFNG demonstrate a loss of TH 1
cytokines and an increase in interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-5 (IL-5), and
interleukin-13 (IL-13) demonstrates an increase in T helper cell type 2 (TH 2) cytokines and is
seen in late stages of CTCL. Interleukin-5 has been associated with the recruitment of
eosinophils and may play a role in the development of pruritis. A pleotropic cytokine,
interleukin-16 (IL-16), has recently been identified as a chemoattractant for CD4+ T cells. The
gradual loss of intracellular IL-16 in T cells is observed from CTCL stage IB and on. The CD8+
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T cells share a TH 1 phenotype and play a role in cell-mediated immunity; their presence may
be consistent with an anti-tumor response (Wong et al, 2011).
Apart from the detrimental physiological manifestations, numerous psychosocial
consequences prevail given the disfiguring nature of CTCL; including negative self-image and
altered perception of self by others (Sampogna et al, 2009). While few studies have focused on
CTCL, there have been studies on psoriasis, a similarly disfiguring disease. Studies have
demonstrated that approximately 40% experience significant anxiety, 38% experience high
levels of worry, 10% of patients with psoriasis experience clinical depression, and 10%
experience suicidal ideation (Gupta, Schork, Gupta, & Ellis, 1993; Gupta, Gupta, Schork, & Ellis,
1994; Fortune, Richards, Main, & Griffiths, 2000; Richards, Fortune, Griffiths, & Main, 2001).
The impact of a disfiguring disease, such as psoriasis, on quality of life has been described as
similar to other chronic diseases, to include cancer, arthritis, and depression (Rapp, Feldman,
Exum, Fleischer, & Reboussin, 1999).
There have been limited studies assessing the quality of life in CTCL patients. Two
studies have examined the psychological and social issues in CTCL patients using the Health
Related Quality of Life (HRQoL) instrument and the SkinDex-29 measurement tool (Sampogna
et al, 2009; Demierre, et al, 2006). Together, these studies established that patients suffer
significant emotional distress related to the visibility of the disease, painful, itching skin, and
worry about the prognosis of the cancer diagnosis. CTCL is an incurable disease that has a
profound effect on patients’ lives about which we know little. This disease can be devastating
and the impact on quality of life is as important as the outcome of treatment (Djulbegovic,
1997). CTCL can be a disfiguring disease with significant consequences affecting the
psychological and emotional status of the patients, as well as their ability to form or maintain
interpersonal relationships. Social rejection, fear of contagion, or avoiding touch is a situation
5

that a person with a chronic skin condition may encounter (Sampogna et al, 2009). In addition,
distorted body image may lead to altered self-perception and dysfunctional intimate
relationships (Sampogna et al, 2009). These issues have not been explored in CTCL patients.
Treatment of CTCL is determined based on the stage of disease at initial presentation.
Skin directed therapies are the treatment of choice in patients with stage IA to IIA disease
(Huber, Staib, Pehamberger, & Scarfetter-Kochanek, 2006; Gardner, Evans, Musiek, Rook, &
Kim, 2009). These therapies may include topical corticosteroids, topical retinoids (e.g.
Bexarotene), phototherapy or any combination of these options. In patients with stage IA
disease that is refractory to topical treatment or progresses on skin directed therapy, the
addition of a systemic treatment may increase the response rate (Huber et al, 2006). Patients
initially diagnosed with stage IIB or higher disease will be treated with more aggressive,
systemic treatment with or without skin directed therapy (Gardner, Evans, Musiek, Rook, & Kim,
2009). Systemic treatment can come in the form of oral biologic modifiers, immunotherapy,
intravenous chemotherapy, or intravenous biologic therapy. Once patients have achieved a
response, identified by a decrease in the amount and visibility of cutaneous lesions, tapering
the treatment regimen or providing maintenance therapy is essential in optimizing duration of
response (Prince, Whittaker, & Hoppe, 2009).
If they achieve good control of their disease, patients with CTCL may live as long as
their normal age matched controls (Demierre et al, 2006). Improving their quality of life may
profoundly impact the patient’s ability to cope with the diagnosis of an incurable disease and
encourage patients to take an active part in managing the symptoms of their disease.
Assessing the predictors of quality of life in patients with CTCL will form a solid foundation for
future intervention studies to improve the control of the symptoms they experience.

6

Statement of the problem
Patients with CTCL may experience profound emotional and physical pain related to their
disease, about which little is known. The areas of affected skin can become significantly pruritic
and painful. In some cases these manifestations can involve greater than 80% of the body
surface area. Little research has focused on the quality of life in patients with CTCL although it
is known to be an incurable, chronic disease. Understanding the predictors of QOL might lead
to better management of disease symptoms, thus improving the quality of life.
Study of purpose
The purpose of this study was to evaluate predictors of quality of life of patients with
CTCL. Information gathered from surveys evaluating depressive symptoms, anxiety, spiritual
well-being, fatigue distress, and the frequency and severity of cutaneous issues may be
beneficial in evaluating the psychosocial and physical consequences of CTCL and how it
influences quality of life. The information will also be the foundation on which to design future
intervention studies and guide clinical practice.
Specific Aims
The specific aims of this descriptive, exploratory, prospective study are to:
1. Examine the factors that may predict the quality of life of patients with CTCL.
2. To evaluate the psychosocial burden (depressive symptoms, anxiety, spiritual wellbeing, and fatigue distress) of CTCL.
3. Examine the influence of depressive symptoms, anxiety, fatigue distress, time since
diagnosis, spiritual well-being, selected demographic variables including age and
gender on the quality of life in patients with CTCL.
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4. To correlate the data obtained from the Skindex-29 and the Skindex-16 to evaluate
the relationship between the two instruments and identify the most appropriate
measurement tool for the given population.
Definition of Relevant Terms
Depressive Symptoms: The impairment of the ability to appreciate the pleasures of life.
Feeling sad or “down in the dumps”, easy to cry even at the smallest issues, everything appears
bleak and hopeless, or a person feels that he or she will never be normal again (DSM IV, 2004).
Spiritual well-being: A feeling of contentment and peace that arises from relationships with self,
others, and a higher power, such as god. (Burkhardt, 1989).
Fatigue: “a distressing persistent, subjective sense of tiredness or exhaustion related to cancer
or cancer treatment that is not proportional to recent activity and interferes with usual
functioning” (NCCN, 2012).
Fatigue Distress: distress or bother caused by fatigue or tiredness (Holley, 2000).
Anxiety: A natural response and a necessary warning adaptation in human beings that can
become a pathologic disorder when excessive. It may, or may not, have a specific external
stimulus, and can manifest physical and affective symptoms as well as changes in behavior and
cognition. (DSM-IV, 2004).
Quality of Life: A complex concept that may be affected by an individual’s level of
independence, psychological state, environment, social relationships, and physical health.
(WHOQOL Group, 1993b).
Significance to Nursing
Care of the patient with Cutaneous T cell lymphoma focuses on management of
distressing symptoms including, but not limited to, pruritis, pain, fatigue, and insomnia
(Sampogna et al, 2009). As the disease progresses, symptoms become more severe and more
8

prevalent. The primary goal is to alleviate suffering and achieve optimal symptom management
for patients experiencing this rare disease. Evaluating for predictors of quality of life in patients
with cutaneous T cell lymphoma will provide insight into what symptoms are the most
distressing and have the most impact on quality of life for these patients. Identifying the most
distressing symptoms will allow us to focus future interventions on improving management of
those symptoms, thereby improving the quality of life for our patients.

9

Chapter II: Review of the Literature
This chapter reviews and synthesizes the current literature of cutaneous T cell
lymphoma. A search was conducted utilizing MEDLINE, PubMed, PSYCHinfo, and CINAHL to
explore the literature regarding the quality of life in patients with CTCL. Keywords such as,
“quality of life”, “Cutaneous T cell lymphoma”, “psoriasis”, “depression”, and “body image” were
used to guide the search. All years and all designs were included. Manual searches of
references were conducted to identify pertinent studies to include in the literature review.
Peer reviewed articles were assessed for scientific rigor and relevance to the current
study. The theoretical framework is discussed followed by a synthesis of the current knowledge
about depressive symptoms and the role of each variable in the development of depressive
symptoms. Finally, the knowledge gaps where additional research is needed are identified.
Theoretical Framework
Maintaining good quality of life is important for patients with CTCL as their disease can
cause unsightly skin manifestations, pain and itching, which in turn, can cause alterations in
body image (Sampogna et al, 2009; Demierre et al, 2006). The symptoms of the disease can
also alter the maintenance and/or development of interpersonal relationships (Sampogna et al,
2009). The concepts represented in the model, provide a foundation for enhancing the quality
of life for patients with an incurable, chronic disease.
The conceptual model used in guiding this study (Figure 1) represents the suggested
influence that demographic data such as age, gender, and ethnicity have on quality of life. The

10

model also represents how psychological symptoms such as depression, spiritual well-being,
fatigue, and anxiety and physical symptoms of the disease are related to the quality of life.

Demographic
Ethnicity
Age
Gender
Level of
Stage education
of disease
Race

Time since diagnosis
Marital status

Physical and Psychological
wellbeing

Quality of Life
Physical
Role
Social
Cognitive

Depression; Anxiety; Spiritual wellbeing; Fatigue; pain, burning,
itching; and other skin symptoms

Emotional

Figure 1. Conceptual Model for the Study
Psoriasis
Psoriasis, also considered a disfiguring skin disease, negatively affects quality of life in
CTCL patients. Many cases of CTCL will present with lesions resembling psoriasis that may
result in misdiagnosis until there is a lack of response to treatment or a progression of disease.
Perrott and colleagues (2000) conducted an observational study to evaluate the relationships
among physician ratings of physical severity, participant self-ratings of quality of life, and
feelings of stigmatization in 101 patients with psoriasis (Perrott, Murray, Lowe, & Mathieson,
11

2000). The psoriasis area and severity index (PASI) was rated by a dermatologist working in
the clinic and three questionnaires were administered to patients receiving psoralen and
ultraviolet (PUVA) light therapy for their psoriasis. The participants responded to seven pairs of
questions to assess the overall quality of life. These questions addressed the level of distress,
disruption to daily routine, disruption to social life, general impact of psoriasis, and perceptions
of others noticing the disease. Participants also completed a 33-item stigmatization scale and
answered questions related to vignettes designed to assess perceptions of prejudice, upset,
discrimination, and embarrassment facing the participant. Participants whose disease
manifested at a younger age expressed more feelings of stigmatization as compared to older
patients with comparable disease severity. On the contrary, older participants reported greater
psychosocial impact, as they perceived more negative impact in how they were viewed by
others but did not feel stigmatized (Perrott et al, 2000).
Approximately two-thirds of patients with psoriasis report the disease has a negative
impact on their everyday life and this approaches 80% in patients with severe disease (Weiss,
Kimball, & Liewehr, 2002; Krueger, Koo, & Lebwohl, 2001). Weiss et al. (2002) conducted a
descriptive, prospective study consisting of 35 consecutive patients. Patients completed selfadministered questionnaires including Satisfaction with Life Scale (SWLS), Euro-QOL (EQ-5D),
and the Medical Outcomes Study Short Form 36 (SF-36). Psoriasis Area and Severity Index
(PASI) was completed by two dermatologist investigators and the Self Assessed PASI (SAPASI)
was completed by the participants. They found that 23% of patients altered their career choice
due to the impact of their disease and 6% reported that they were ‘often’ or ‘always’ depressed
due to their condition. In populations with chronic, disfiguring, and uncomfortable diseases,
suicide is a concern (Weiss et al, 2002).
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In secondary analysis of several observational studies Gupta and Gupta (1998)
conducted a descriptive, observational study of 450 patients using the Carroll-Rating Scale for
Depression (CRSD). They reported that 9.7% of patients experienced suicidal ideation with
5.5% experiencing it at the time of the study. Suicidal ideation was associated with higher
depression scores and higher self- rating of disease (Gupta & Gupta, 1998).
Gelfand, Feldman, Stern, Thomas, Rolstad, and Margolis (2004) conducted a study
evaluating the use of a comprehensive questionnaire to describe the determinants of quality of
life in psoriasis patients. Gelfand and colleagues found that as skin involvement with psoriasis
becomes more extensive, patients suffer more impairment in their quality of life. They also
reported a weak negative correlation with quality of life and age, thereby identifying younger
patients as being more impaired than older patients. In fact, young female patients were more
impacted by their disease (Gelfand et al, 2004).
The studies evaluating quality of life in patients with psoriasis revealed that quality of life
was better for patients in the later years of life. The studies also emphasize how the
appearance of their skin influences decisions to participate in social activities and the types of
careers that were chosen. Patients suffering with a chronic, visible disease may avoid social
situations leading to a tendency to withdraw from society resulting in isolation, thereby
increasing the presence of depressive symptoms. Patients with a diagnosis of indolent cancer
experience a good quality of life when the symptoms of disease are minimal. Identification of a
population that may need additional psychological support would allow health care providers to
assist the patient to achieve and maintain a good quality of life.
Quality of Life in Patients with Cutaneous T Cell Lymphoma
There is limited research evaluating the quality of life in CTCL patients. Sampogna and
colleagues (2009) conducted an observational, cross-sectional study to evaluate the
13

psychological distress and health related quality of life in 71 CTCL patients. Participants
completed the Skindex-29, and EORTC QLQ-C30 questionnaires to assess their quality of life.
The results demonstrated that the presence of the disease affected social interactions and
intimacy with loved ones. They also found that impairment in global health status, emotional
well-being, fatigue, and insomnia were worse in patients with advanced stage disease
(Sampogna, et al, 2009).
Demierre and colleagues (2006) evaluated the quality of life of 630 CTCL patients
(Demierre, Gan, Jones, & Miller, 2006). A four page self-administered questionnaire was mailed
or completed online by patients who were members of the United States Mycosis Fungoides
Foundation. The study was designed to evaluate patients’ perspectives regarding the impact of
CTCL and its treatment. Results demonstrated that 62% of participants reported they felt
unattractive due to their disease. Respondents also noted that they felt ashamed of their
disease when it was mistaken for a contagious condition. Greater than 80% of participants felt
bothered by the itching, scaling, and skin redness. The disruption in the lives of CTCL patients
was attributed to fatigue (66%) that resulted in days missed from work or school, and 43%
stated that they felt they couldn’t provide for their families. Limitations of this study included
that some patients have limited access to health care and may not know of the United States
Mycosis Fungoides Foundation (Demierre et al, 2006).
A smaller quality of life study was conducted by Demierre, Tien, and Miller (2005). This
was a monocenter, cross-sectional study and consisted of 22 patients with CTCL with stage of
disease ranging from IA to IVB. Ten patients had stage IA to IIA disease and 12 patients
exhibited late stage disease (IIB-IVB). Mean age of participants was 63 years, majority of
participants were white, and there were equal numbers of male and female participants. All
participants completed a general HRQoL instrument (FACT-G) and a disease specific HRQoL
14

instrument (Skindex-29). They found that participants with higher stage disease reported a
worse quality of life. Even participants with lower stage of disease reported alterations in their
quality of life, and this became more pronounced as the disease progressed. Demierre et al.
(2005) also reported that the impact of CTCL on functioning appeared to be similar to studies
conducted for participants with psoriasis assessed utilizing the Skindex-29 questionnaire. Of
note, the emotional status of CTCL participants was not as affected as was reported in the
psoriasis participants although this may be attributed to the difference in the age of the
participants, as psoriasis usually affects a younger population. A limitation of this study was the
very small sample size (Demierre et al, 2005).
Duvic et al (2001) conducted a study to evaluate the effects of oral Bexarotene in
patients with CTCL. The patients completed a general (Spitzer) QOL questionnaire and a nonvalidated CTCL specific QOL questionnaire once monthly for four months. A total of 94 patients
with a confirmed diagnosis of CTCL were enrolled. The QOL scores did not change significantly
throughout the study. The CTCL specific QOL instrument showed significant improvement in
the symptoms from baseline to end of study. The results showed that pruritis improved from
moderate to mild and satisfaction with appearance improved from moderately dissatisfied to
neutral. Notably, the patients who received treatment with oral bexarotene reported better
quality of life assessments even if they were considered non-responders to the medication
(Duvic et al., 2001).
More recently, a study was conducted by Wright and colleagues (2013) to evaluate the
prevalence and severity of pruritis and quality of life in patients with cutaneous T cell lymphoma
(Wright, Wijeratne, Hung, Gao, Whittaker, Morris, Scarisbrick, & Beynon, 2013). They recruited
100 patients for participation in the study. Patients who met eligibility criteria completed the
skindex-29 and the visual analogue scale for itch (VASitch). The Skindex-29 consists of 30
15

questions with one question not included in the analysis. Of the participants, 88% reported
itching with 46% of these stating that it was often or always problematic. This study was
effective in evaluating the presence of pruritis in the study participants; however, this patient
population experiences a myriad of symptoms that were not assessed in this study (Wright et
al., 2013).
There have been no studies conducted to evaluate spiritual well-being in CTCL patients.
Research investigating spiritual well-being in patients with chronic, incurable, cancer, revealed
negative correlations between spiritual well-being and ineffective coping styles such as
avoidance, helplessness, and hopelessness (Cotton, Levine, Fitzpatrick, Dold, & Targ, 1999;
Nelson, Rosenfeld, Breitbart, & Galietta, 2002; Krupski, Kwan, Fink, Sonn, Maliski, & Litwin,
2006; Bredle, Salsman, Debb, Arnold, & Cella, 2011). Whereas, positive spiritual well-being
played an important part in effective coping and increased patient’s QOL (Dapueto, Servente,
Francolino, & Hahn, 2005; Whitford, Olver, & Peterson, 2008).
In summary, only limited research has been reported about the QOL of patients with
cutaneous T cell Lymphoma, and with one exception, those studies have had small sample sizes
and none has focused on predictors of quality of life in this patient group. The negative effect
of depressive symptoms, fatigue, and anxiety, on QOL has been documented in patients with
cancer (Butow, Coates, & Dunn, 1999). In patients with advanced cancer, spiritual well-being
has been identified as an important factor in alleviating depressive symptoms, decreasing
anxiety, and preserving or restoring good QOL (Tate & Forchheimer, 2002; Bredle, Salsman,
Debb, Arnold, & Cella, 2011; Daugherty et al, 2005). Future research should investigate the
physical symptoms, depressive symptoms, anxiety, fatigue distress, and spiritual well-being as
factors that influence QOL in this special population. Further research is needed using a larger
and more diverse sample.
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Chapter III: Methods
This chapter discusses the design of the study, sample selection including inclusion and
exclusion criteria, and the setting for the study. The measurement instruments that were used
in the study are described and psychometric properties are delineated. The procedures for
institutional approval, informed consent, and the analysis of the data are also described. This
was a descriptive, exploratory, prospective study designed to examine the predictors of quality
of life in patients with CTCL.
Institutional approvals
The Moffitt Scientific Review Committee (SRC) and the USF Institutional Review Board
(IRB) received submissions of the protocol for their review. Written approval was obtained
from both organizations and the study began in February, 2013 (Appendix A). The study took
place at Moffitt Cancer Center & Research Institute in Tampa, Florida and was conducted over a
seven month period.
Setting and Sample
CTCL participants were referred to the study from the cutaneous T cell lymphoma and
the malignant hematology clinics at Moffitt Cancer Center between February 2013 and
September 2013. Following approval by the Moffitt SRC and the USF IRB, access to the
participants was based on referral by the physicians, nurses, and the manager in the cutaneous
clinic at Moffitt Cancer Center. Seventy-five patients who had a confirmed diagnosis of CTCL
were recruited for participation in the study. Inclusion criteria were: being able to read and
understand English, being 18 years or older, and being alert and able to provide informed
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consent. Exclusion criteria included minor children, patients with other new diagnoses of cancer
within one year, and patients with altered mental status who were unable to provide consent.
Participants were informed that the data will be de-identified and will remain anonymous.
Measures
The measures that were used in this study are described below. The individual scales
are appended (Appendix B).
Quality of life
The Quality of Life Core Questionnaire of the European Organization for the Research
and Treatment of Cancer (EORTC QLQC-30) was used to measure CTCL patients’ QOL. This
instrument consists of 30 items arranged within six scales of aspects of functioning (Dirmaier,
Zaun, Koch, Harfst, & Schulz, 2004). These scales included physical (Cronbach’s alpha 0.720.86), role (Cronbach’s alpha 0.83-0.91), social (Cronbach’s alpha 0.74-0.86), cognitive
(Cronbach’s alpha 0.56-0.70), and emotional functioning (Cronbach’s alpha 0.69-0.87), and
global quality of life (Cronbach’s alpha 0.81-0.93). In addition, the scale consisted of three
symptom subscales, fatigue (Cronbach’s alpha 0.79-0.84), nausea/vomiting (Cronbach’s alpha
0.60-0.77), and pain (Cronbach’s alpha 0.73-0.76), and six symptom items including financial
problems, constipation, diarrhea, dyspnea, sleep disorder, and loss of appetite. Items are
measured on a four-point Likert type scale. The scores of the six functioning scales were
calculated by adding up the raw scores of a scale and dividing by the number of items on that
scale. The scores were mapped for each parameter onto a scale of zero-100, with 100
representing the highest level of functioning. The symptom scales were calculated in a similar
fashion with the exception that higher scores indicated a higher symptom burden. For the
purposes of this study, only the total score was used in the analyses. Cronbach’s alpha for the
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EORTC QLQ-C30 version 3, has been reported to be greater than 0.70, representing acceptable
internal consistency (Dirmaier et al., 2004).
Dermatology related quality of life
The Skindex-29 is a disease specific instrument used to measure the effects of
dermatological disease on the quality of life in CTCL patients. This instrument is a 29-item
questionnaire focusing on three dimensions: Symptoms (seven items), emotions (10 items), and
functioning (12 items). The Skindex-29 is a five point Likert type scale. The overall score, as
well as the individualized scores for each dimension are converted to a scale of zero (no impact
on QOL) to 100 (maximum impact on QOL). Internal consistency reliability has ranged from
0.86-0.95 (Chren, Lasek, Flock, & Zyzanski, 1997).
The Skindex-16 is a shortened version of the Skindex-29, addressing 16 questions that
measure bother rather than frequency of symptoms. It is because of this difference the
SkinDex-16 and SkinDex-29 will be evaluated to determine if one instrument is superior for use
in this specific population. The SkinDex-16 is scored on a bipolar scale with seven response
choices ranging from “never bothered” to “always bothered”. There are three subscales
consisting of symptoms, emotions, and functioning. Scores range from zero-100 and internal
reliability has been demonstrated with a Cronbach’s alpha of 0.86-0.93 (Chren, Lasek, Sahay, &
Sands, 2001).
Depressive Symptoms
The Center for Epidemiologic Studies Depression (CES-D) scale is a widely used selfreport instrument to measure depressive symptoms. The CES-D consists of 20 items and is
purported to measure important components of depressive symptoms including feelings of
helplessness and hopelessness, feelings of guilt and worthlessness, depressed mood,
psychomotor retardation, loss of appetite, and sleep disturbances. There are 20 items that
19

have been clustered into four dimensions 1) depressed affect 2) positive affect 3) somaticretarded activity and 4) interpersonal relations (Radloff, 1977). Scores on the CES-D can range
from zero-60. Although the CES-D does not diagnose depression, a total score of 16 or higher
requires further screening for major depression, and a score greater than 23 may indicate
probable depression. Cronbach’s alpha for the CES-D has been reported to be greater than
0.80 representing good internal consistency (Schroevers, Sanderman, Sonderen, & Ranchor,
2000).
Anxiety
The state-trait anxiety inventory is an instrument commonly used to measure state and
trait anxiety (Spielbeger, Gorsuch, Lushene, Vagg, & Jacobs, 1983). The Y form consists of 20
items evaluating state anxiety and 20 items evaluating trait anxiety. All items are scored on a
four point Likert-type scale, from “almost never” to “almost always”. High levels of anxiety are
indicated by higher scores. Internal consistency coefficients range from 0.86 to 0.95
(Spielberger et al., 1983). Only the state anxiety inventory will be used in this study.
Spiritual Wellbeing
The Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being scale (FACITSP) was developed to address the need for a broad measure of spiritual well-being (Cella,
Tulsky, Gray, Sarafian, Linn, et al., 1993). This is a 12 item measurement tool consisting of
three subscales (peace, meaning, and faith). This is a self-administered, five point Likert-type
scale that measures distress and is scored on a zero (not at all) to four (very much) scale.
Higher scores represent greater spiritual well-being. This measurement tool has been validated
in cancer patients and patients receiving hospice services. The Cronbach’s alpha coefficient for
the 12 item instrument has been reported to be 0.81-0.88 (Cella, et al. 1993; Bredle, et al,
2011).
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Cancer Related Fatigue
Cancer Related Fatigue Distress Scale (CRFDS) evaluates the distress experienced by
patients who suffer from the symptom of fatigue (Holley, 2000). The instrument consists of 20
items and encompasses the cognitive, psychological, physical, social, and spiritual domains. It
is scored on an 11 point Likert type scale, zero (no distress) to 10 (severe distress). The scores
are summed and range from 0-200 with higher scores indicating a higher level of fatigue
distress. There are three additional questions rating fatigue at the time of completion of the
survey, worst fatigue over the past week and usual amount of fatigue. There are three
additional questions addressing level of fatigue over the past week, usual level of fatigue, and
level of fatigue now. The CRFDS has an alpha coefficient of 0.98 (Holley, 2000).
Demographic form
Demographic data was obtained to describe the characteristics of the sample. The
investigator developed demographic form constructed for the study included gender, race, age,
marital status, type and stage of disease, time since diagnosis, religious affiliation, and level of
education.
Procedures
After the protocol was approved by the Moffitt SRC and the USF IRB, physicians began
to refer patients who were identified as eligible for participation. Once referred, the patients
underwent further screening by the investigator to confirm eligibility. Following confirmation of
eligibility, patients were approached for participation. The patient was escorted to an exam
room in the cutaneous or the hematology clinic to ensure privacy and confidentiality. The
consent and protocol of the study was explained in detail and questions were answered to the
patient’s satisfaction. If the patient consented to participation, one copy of the consent
remained in the research folder and the patient received a copy of the consent. Data collection
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began with administration of the Skindex-29, QLQ-C30, CES-D, STAI, FACIT-Sp, cancer related
fatigue distress scale, Skindex-16, and the demographic form. Completion of these forms
completed the patient’s participation in the study.
Analysis of data
All data was analyzed using SPSS version 21 statistical software (IBM, Somers, NY). To
analyze demographic data, descriptive statistics were used including means, standard
deviations, frequencies and percentages. All multi-item instruments were evaluated for internal
consistency and reliability and alpha coefficients were obtained. To meet the specific aims, the
following analyses were conducted:
1. To examine factors that may predict the quality of life of patients with CTCL, means and
standard deviations were calculated for the EORTC QLQ C-30, Skindex-29 and Skindex16.
2. To evaluate the psychosocial burden (depression, anxiety, fatigue, and spiritual wellbeing) of CTCL, means and standard deviations were calculated for the STAI, CES-D,
CRFDS, and FACIT-Sp.
3. To examine the influence of depression, anxiety, time since diagnosis, selected
demographic variables including age and gender, as predictors of quality of life of CTCL,
were calculated using multiple regression analysis.
4. To compare the Skindex-29 and the Skindex-16, convergent validity was assessed using
Pearson’s correlation coefficient.
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Chapter Four: Results
This chapter presents the results of the study. First the sample is described; this is
followed by means and standard deviations for all of the measures used in the study. Finally,
specific aims are addressed.
Sample
The sample consisted of 75 participants, with slightly more men than women, all with a
confirmed diagnosis of cutaneous T cell lymphoma. The majority of participants were
diagnosed with stage IA, IB, or IIA disease. The majority of the patients were white, married,
and had a Christian religious affiliation (Table 3). The age of the participants ranged from 24 to
88 years of age, with a mean of 62.5 years and a standard deviation of 14.6. The range of
years of education was 10 to 24 years. Of the participants, 22 (29.3%) had at least some high
school education and most (N=53, 70.5%) had college education (Table 4).
Table 3. Frequencies and Percentages of the Demographic Variables of the Sample
(n=75).
Variable

Frequency

Percent

Male

41

54.7

Female

34

45.3

54

72

Gender

Ethnicity
White
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Table 3 (continued)
Black
Hispanic

16

21.3

5

6.7

Stage of Disease
IA

24

32

IB

19

25.3

IIA

4

5.3

IIB

8

10.7

IIIA

2

2.7

IIIB

6

8.0

IVA

10

13.3

IVB

1

1.3

Marital status
Married

51

68

Single

12

16

Widowed

6

8

Divorced

6

8

Religion
Non-Catholic Christian

44

58.7

Catholic

24

32.0

Jewish

3

4

None

2

2.7

Muslim

1

1.3

Other, non-specified

1

1.3
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Table 4. Mean, Standard Deviations, and Range for Demographic Variables of the Sample
(n=75).
Variable

Mean

Range

SD

Age

62.5

(24-88)

14.6

Years of education

15.0

(10-24)

2.8

5.0

(1-31)

5.2

Time since diagnosis

Descriptive Data
The means and standard deviations of depressive symptoms, anxiety, fatigue distress,
and spiritual well-being scores are delineated in Table 5. Also included are the mean and
standard deviation of the outcome variable, quality of life.
Table 5. Means and Standard Deviations of Patients’ scores on Quality of Life, Anxiety,
Depressive Symptoms, Spiritual Well-being, and Fatigue Distress. (N=75)
Variable

Range

Mean

SD

Depressive symptoms

0-60

11.0

11.9

Anxiety

20-80

34.7

14.6

Fatigue distress

0-200

48.6

55.5

Quality of life

0-100

68.9

22.4

Spiritual well-being

0-156

118.5

30.2

All instruments used in this study were tested for their reliability when utilized among
this specific population of cutaneous T cell Lymphoma patients. The Cronbach’s alpha
coefficients were strong with all being greater than 0.70, and most of them being greater than
0.90 (Table 6).
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Table 6. Reliabilities of the Measurement Instruments
Instrument

Cronbach’s alpha

Cancer related fatigue distress scale

0.99

SkinDex-29

0.98

SkinDex-16

0.96

State anxiety

0.96

CES-D

0.94

EORTC QLQ-C30

0.92

FACIT-Sp

0.77

The items of the SkinDex-29 were evaluated for the rate of responses to each item
(Table 7). Responses included were “never”, “rarely”, “sometimes”, “often”, and “all the time”.
Skin itching and skin irritation were the most frequently reported symptoms. The highest mean
scores were found in the most frequently occurring symptoms.
Table 7. Frequency, Percent, Means, and Standard Deviations of Responses to SkinDex-29
Items
Item

Frequency

Percent

Mean

SD

Skin itching

70

93

58.3

29.2

Skin irritated

68

91

54.0

29.1

Worry about severity

67

89

55.7

31.2

Worry about progression

66

88

57.7

31.6

Annoyed

64

85

50.7

32.4

Skin sensitive

64

85

57.0

33.5

Frustrated

63

84

51.7

33.0

Depressed

51

68

34.7

32.9
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Table 7 (continued)
Disrupted sleep

51

68

38.0

34.7

Skin pain

46

61

32.7

32.9

Skin burns/stings

46

61

33.7

34.8

Embarrassed

44

59

32.0

34.5

Worry about scars

44

59

29.7

31.5

Ashamed

43

57

30.7

33.8

Tired

43

57

35.7

37.2

Affects social life

42

56

31.7

35.0

Angry

39

52

30.7

35.5

Affects closeness to loved ones

39

51

23.0

28.7

Affects work/hobbies

36

48

28.0

36.8

Water bothers

36

48

27.0

34.6

Affects interactions with others

36

48

25.0

31.6

Affects desire to be with others

36

48

26.0

32.7

Humiliated by skin

35

47

23.0

29.6

Difficult showing affection

35

47

23.0

31.0

Stay at home

34

45

25.3

34.3

Do things alone

33

44

23.0

32.6

Interferes with sex life

33

44

23.0

32.5

Skin bleeds

31

41

18.7

26.7

Influence of Predictor Variables on QOL
The predictor variables that demonstrated a significant bivariate correlation with QOL
were included in the regression analysis. A spearman correlation was utilized in the evaluation
of a relationship among stage of disease and quality of life. The variables of stage of disease,
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depressive symptoms, anxiety, spiritual well-being, and fatigue distress all demonstrated a
significant P value of less than 0.001 (Table 8). The correlations reveal that as the symptoms
of depression, anxiety, and fatigue distress increase, the QOL decreases. Also, because the
SkinDex instruments demonstrate a negative correlation, this shows that as the cutaneous
manifestations become worse patients experience worse QOL. Spiritual well-being had a
positive correlation with QOL, meaning that as spiritual well-being increases the QOL increases.
Table 8. Correlation of Predictors with Quality of Life (n=75)
Variable

r

P

Stage of disease

-0.450

<0.001

Depressive symptoms

-0.710

<0.001

Anxiety

-0.641

<0.001

0.729

<0.001

Fatigue distress

-0.710

<0.001

SkinDex-29

-0.644

<0.001

SkinDex-16

-0.569

<0.001

Spirituality

Categorical variables were evaluated using an independent samples t-test (Table 9).
Quality of life scores did not differ by ethnicity, marital status, or gender and thus, were not
significantly related to QOL. Therefore, these variables were omitted from the regression
analysis.
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Table 9. Independent Samples t-Test Results of Ethnicity, Marital Status, and Gender with QOL
Variable

N

mean

t

P

White

54

71.1

-1.409

0.163

Non-white

21

63.1

Married

51

72.5

-1.909

0.064

Not married

24

61.1

Male

41

72.6

1.578

0.119

Female

34

64.5

Ethnicity

Marital status

Gender

The subsequent regression analysis (Table 10) revealed that only depressive symptoms
(CES-D) and stage of disease had a significant relationship with QOL. More specifically, as the
stage of disease increased, there was a decrease in the QOL. Likewise, as the depressive
symptoms increased the QOL decreased. These results identify stage of disease and depressive
symptoms as having statistically significant influences on the outcome, QOL.
Table 10. Regression of Predictor Variables on QOL
Variable
Stage of disease

B

Standard error of B



t

P

-11.028

3.719

-0.240

-3.0

0.004

Depressive symptoms -0.701

0.295

-0.373

-2.4

0.020

Anxiety

0.204

0.243

0.133

0.8

0.404

Spiritual well-being

0.189

0.142

0.255

1.3

0.187

Fatigue distress

-0.024

0.069

-0.353

0.7

-0.060

SkinDex-29

-0.105

0.117

-0.115

0.896

-0.374
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Relationship Among the SkinDex-16, SkinDex-29, and the Predictor Variables
To evaluate the relationship between the SkinDex-16 and Skindex-29, correlations were
conducted among the subscales as well as the total scores for both. The results of the
correlations revealed a strong relationship among the subscales of each instrument and within
each instrument as well as among the total scores of both instruments (Table 11).
Table 11. Correlation of SkinDex-29 and SkinDex-16 Measurement Tools (n=75)
Variablea

SD29E

SD29F

SD29S

SD29E

-

-

-

-

SD29F

0.859*

-

-

SD29S

0.702*

0.802*

-

SD29T

0.926*

0.958*

0.895*

SD16E

0.847*

0.732*

0.651*

SD16F

0.806*

0.857*

SD16S

0.563*

SD16T

0.815*

a

SD29T

SD16E

SD16F

SD16S

SD16T

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.805*

-

-

-

-

0.621*

0.825*

0.830*

-

-

-

0.634*

0.781*

0.708*

0.747*

0.619*

-

-

0.817*

0.755*

0.859*

0.949*

0.900*

0.870*

-

E, Emotions; F, Function; S, Symptoms; T, Total; *Significance <0.001

Each predictor of fatigue distress, depressive symptoms, anxiety, and spirituality, the
demographic variables of stage of disease, age, gender, ethnicity, and level of education, were
correlated with the SkinDex-16 and SkinDex-29. The results of the correlations with SkinDex-29
revealed that as the cutaneous symptoms become worse, spiritual wellbeing decreases (Table
12). The correlations of significant predictor variables and SkinDex-16 are also presented in
Table 12. There were negative correlations noted between the SkinDex-16 and spirituality and
SkinDex-16 and age. This demonstrates that as participants age they were less likely to have
or complain of cutaneous symptoms.
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Table 12. Correlation of Individual Predictors with the SkinDex-29 and the SkinDex-16
Correlation

SkinDex-29
r

SkinDex-16
P

r

P

Anxiety

0.691

<0.001

0.697

<0.001

Depressive symptoms

0.736

<0.001

0.636

<0.001

-0.744

<0.001

-0.705

<0.001

Fatigue distress

0.787

<0.001

0.745

<0.001

Stage of disease

0.281

0.007

0.251

0.015

Age

-0.327

0.002

-0.372

0.001

Level of Education

-0.258

0.013

-

-

Spirituality

An independent samples t-test was conducted to evaluate the variables of ethnicity,
gender, and marital status for the presence of a significant relationship with QOL (Table 13).
Ethnicity and gender were significantly associated with both the Skindex-16 and the Skindex-29.
Marital status did not demonstrate a significant relationship with the Skindex-16 and Skindex29.
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Table 13. Independent Samples t-Test Results of Ethnicity, Marital Status, and Gender with
SkinDex-29 and SkinDex-16.
Variable

N

mean

White

54

44.7

Non-white

21

31.8

Married

51

32.9

Not married

24

40.8

Male

41

27.3

34

45.1

White

54

47.1

Non-white

21

30.2

Married

51

31.2

Not married

24

42.9

Male

41

26

Female

34

45.6

t

P

SkinDex-29
Ethnicity
2.108

0.038

1.309

0.195

-3.350

0.001

2.392

0.019

1.690

0.095

-3.163

0.002

Marital status

Gender

Table 13 (Continued)
Female
SkinDex-16
Ethnicity

Marital status

Gender

When the predictor variables were regressed onto the SkinDex-29, the variables of
depressive symptoms, fatigue distress, and age revealed statistically significant relationships
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(Table 14), indicating that these variables exhibit significant relationships with cutaneous
symptoms.
Table 14. Regression of Predictor Variables onto SkinDex-29 (n=75)
Variable

B

Standard error of B



t

P

Stage of disease

6.153

4.005

0.122

1.536

0.129

Depressive symptoms

0.596

0.295

0.290

2.021

0.047

Anxiety

-0.203

0.254

-0.121

-0.801

0.426

Spirituality

-0.080

0.145

-0.098

-0.550

0.584

Fatigue distress

0.204

0.067

0.463

3.055

0.003

Age

-0.299

0.150

-0.178

-2.003

0.049

Gender

5.619

3.639

0.115

1.544

0.127

Ethnicity

-0.123

4.606

-0.002

-0.027

0.979

Education

0.100

0.648

0.011

0.155

0.878

The regression of predictor variables onto the SkinDex-16 showed that fatigue distress
was the only variable with a statistically significant relationship. The variable of education was
excluded from this analysis due to a lack of correlation with the SkinDex-16 instrument. The
positive correlation between the SkinDex-16 and fatigue distress shows that as skin
manifestations become more bothersome, fatigue distress increases (Table 15).
Table 15. Regression of Predictor Variables onto SkinDex-16 (n=75)
Variable
Stage of disease

B

Standard error of B



t

P

5.201

5.017

0.090

1.037

0.304

Depressive symptoms -0.202

0.369

-0.085

-0.549

0.585

Anxiety

0.381

0.316

0.196

1.205

0.232

Spirituality

-0.189

0.181

-0.202

-1.042

0.301

Fatigue distress

0.177

0.083

0.347

2.128

0.037

-0.359

0.187

-0.185

-1.923

0.059

Gender

7.540

4.527

0.134

1.666

0.101

Ethnicity

-4.825

5.752

-0.077

-0.839

0.405

Age
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Chapter 5 Discussion, Implications and Conclusions
This chapter discusses the findings presented in Chapter 4. The sample and descriptive
data are interpreted. The influence of the predictor variables on quality of life and the
relationship among the SkinDex instruments and the predictor variables also are discussed.
Sample
The sample involved 75 participants with cutaneous T cell lymphoma (CTCL). Most
participants were male with stage IA disease. The mean age of the participants was noted to
be approximately 62 years, which supports prior research that CTCL is a disease of a slightly
older population. However, the age range from 24-88 years reinforces that CTCL can affect
anyone along the age spectrum. A power analysis was conducted prior to data collection, and a
sample size of 83 was recommended. This was calculated where the Pearson’s correlation
coefficient was 0.3 and the test of significance assumed alpha 0.05, with power 0.80. The
sample size dictated by the power analysis was not achieved due to a short recruitment time
and a single researcher available to recruit participants. Even though the goal sample size of 83
was not obtained, the sample size of 75 produced statistically significant results.
Descriptive Data
The mean of the CES-D, which evaluates depressive symptoms, was noted to be 11 on a
scale of 0 to 60. It has been documented that a score of 16 or higher requires further
evaluation for the presence of major depression (DSM-IV, 2004). Furthermore, a score of 23 or
greater may indicate probable depression. The mean score in the CTCL population was much
lower than either of these thresholds, indicating that depressive symptoms were not prevalent
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or severe in this sample. Some of this variability may be due to the fact that most participants
(62.6%) had low stage disease (< stage IIA) and only 36% had advanced stage disease (>
stage IIB). Given that more than half of this group had early stage disease, the low mean
score on the CES-D should not be surprising and may not be representative of the patients with
higher stage disease (>stage IIB).
The state portion of the state-trait anxiety inventory was used to evaluate the presence
of anxiety in the sample. Their mean score was 34.73, while the scores can range between 20
and 80. The mean result demonstrates that on average anxiety is low in this group. A majority
of the participants in the sample (47 of 75) had disease that required minimal to no treatment.
It would be expected that an incurable disease would cause an increase in the amount of
anxiety experienced by participants; however, the results revealed a contrary outcome. The
realization that the treatment regimen for these participants is not invasive and should not have
an impact on their normal activities of daily living, may lead to a lower level of anxiety for most
this sample or may allow them to use the defense mechanism of denial.
The presence of fatigue in cancer patients has been well documented, and is reported to
affect approximately 75% of cancer patients (Yennurajalingam, Palmer, Zhang, Poulter, &
Brurera, 2008). It has also been documented in the CTCL population with higher levels of
fatigue found in patients with higher stage of disease (Demierre et al, 2005). The cancer
related fatigue distress scale (CRFDS) has been validated and utilized to evaluate how
distressing fatigue can be for patients with cancer. Most patients reported the presence of
fatigue (n=52) but few reported a high level of distress related to the fatigue. The mean score
for fatigue distress was 48.6, much less than the highest score of 200. These results
demonstrate that high levels of fatigue distress were not frequently reported by this sample.
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Quality of life was moderately high with the mean score for the sample being reported
as 68.9 on a scale of 0 to 100. This mean score demonstrates that the sample has been able
to maintain a very good quality of life even though they have a diagnosis of an incurable
cancer. Again, these results may be more representative of participants with minimal disease
burden and therefore, minimal to no need for systemic treatment. It is expected that patients
with more advanced disease would experience a decrease in their quality of life. This may be
attributed to symptoms of disease, side effects of treatment, or the physical and mental burden
of treatment. Overall, these results seem to indicate that the quality of life for the participants
in this group is good. Future studies should include patients with more advanced disease.
The variable of spiritual well-being was measured by the FACIT-Sp and revealed a mean
score of 118.49 on a scale of 0 to 156. So, the results from this study demonstrate that
participants in the sample, who were predominantly Christian, had moderately high reports of
spiritual well-being. It has been reported that high levels of spiritual well-being are associated
with higher levels of quality of life for cancer patients (Bredle, et al, 2011).
All of the instruments used in this study have been validated and shown to be reliable
(Dirmaier et al., 2004; Chren et al., 1997; Chren et al., 2001; Schroevers et al., 2000;
Spielberger et al., 1983; Cella, et al. 1993; Bredle, et al, 2011; Holley, 200). The reliabilities for
each measurement instrument utilized in this study were calculated and most demonstrated
high reliabilities. All instruments demonstrated alpha coefficients greater than 0.90 with the
exception of the FACIT-Sp, which demonstrated an alpha coefficient of 0.77. Although lower
than the other instruments, this alpha of 0.77 is certainly acceptable. The CTCL population has
not been studied extensively; therefore, the results of the reliability coefficients are important in
this population to lay a foundation for future research.
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Each of the items on the SkinDex-29 instrument was evaluated to determine which
cutaneous related symptoms were the most frequently reported. The number of responses
included participants who answered “rarely”, “sometimes”, “often”, and “all the time”. The
most frequent symptoms reported were skin itching and skin irritation. The least frequently
reported symptoms included how the disease affected interaction with others and skin bleeding.
It was not stratified to evaluate how many participants answered at each of the four levels.
This would be helpful in determining how much each symptom affected the participants and
should be included in future research.
Influence of Predictor Variables on Quality of Life
Correlations of the predictor variables were conducted prior to the regression to
evaluate if there were relationships worthy of investigating. The variables of gender and
ethnicity (white vs. non-white) were evaluated using an independent samples t-test. This
method revealed non-significant differences among these groups on their QOL scores and they
were excluded from the subsequent regression analysis. Stage of disease was evaluated using
a Spearman correlation and was found to have a significant relationship with the outcome
variable QOL. Bivariate correlations were calculated between the continuous variables and
QOL. The variables that demonstrated a statistically significant relationship with QOL were
included in the regression analysis. Ethnicity and gender did not demonstrate significant
correlation with QOL and therefore, were not included in the regression analysis.
The regression analysis revealed that only depressive symptoms (p=0.039) and stage of
disease (p=0.002) were identified as predictors of QOL in the sample. The influence of
depressive symptoms on QOL in patients with a diagnosis of incurable cancer has been
demonstrated in previous research (Warmenhoven et al., 2011). The concurrent occurrence of
multiple somatic symptoms, especially when they are uncontrolled, has been found to be
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predictive of the development of depressive symptoms (Chen & Chang, 2004; Lloyd-Williams,
Shiels, Taylor, and Dennis, 2009). Participants with advanced stage of CTCL would be expected
to have worse QOL as opposed to participants with lower stage of disease because they have
more cutaneous and quite possibly systemic symptoms (Weiss et al, 2002, Gelfand et al, 2004).
Research has shown that in patients with chronic lymphocytic leukemia, another type of
indolent disease, good QOL is preserved until they experience an increase in the frequency of
symptoms (Shanafelt et al, 2007). Patients diagnosed with stage I CTCL have been shown to
have a normal life span and may not be as affected by the psychological side effects of having
an incurable diagnosis (Demierre et al, 2006). This lends support to the lack of influence of
anxiety as a predictor of QOL in this study. Anxiety would be expected to be a significant
predictor of QOL in a population with more advanced disease.
Spiritual well-being did not exhibit a significant relationship as a predictor of QOL.
These findings might have been different if the sample included more participants with
advanced stage disease. It has been shown that an increased level of spiritual well-being is
associated with a lower level of depression experienced by patients with cancer (Bredle, et al,
2011); thus, QOL would be expected to be improved by decreased depression and improved
spiritual well-being.
Fatigue distress was also not identified as a predictor of QOL. Again, this finding would
be expected in this sample with so many participants having low stage disease. The majority of
these patients (n= 54) were receiving non-invasive therapy in the form of topical creams used
as needed or exposure to ultraviolet light on a weekly basis and reported low levels of fatigue
distress. It is known that patients with advanced stages of cancer experience fatigue, either as
a side effect of the disease process or as a side effect of the treatment of their cancer
(Demierre et al, 2006). Future studies should focus on patients with higher stage disease.
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Surprisingly, the SkinDex-29, a dermatologic specific measure of QOL, did not exhibit a
significant influence as a predictor of QOL in this sample. Previous research has shown that
dermatological symptoms, more specifically pruritis, are the most distressing symptoms for
patients with CTCL (Demierre et al, 2005). The results of this study speak to how important
stage of disease is as a predictor of QOL.
Relationship Among The SkinDex-16, SkinDex-29, and the Predictor Variables
One of the specific aims of the study was to evaluate which dermatologic specific
measurement tool was more appropriate to use in the study of CTCL patients. The SkinDex-29
has been used more frequently in dermatologic studies. It measures how frequently symptoms
are experienced. The SkinDex-16 was derived from the SkinDex-29 and measures how severe
the symptoms are when they are experienced. In order to establish the relationship between
these two instruments bivariate correlations were conducted between each of the subscales and
the total score for each instrument. As presented in Chapter 4, the Pearson correlation
coefficient between the two scales was high (r=0.86; p<0.001). This finding is not surprising
given that the SkinDex-16 was derived from the SkinDex-29, and provides additional evidence
of construct validity for the newer Skindex-16. In addition, the subscales of the shortened
Skindex-16 were strongly correlated with the matching subscales of the Skindex-29 (r=0.760.86; p<0.001). This offers further support for the construct validity of the Skindex-16.
Bivariate correlations were conducted among the predictor variables and each SkinDex
measurement instrument. Because the correlations between the subscales and the total scores
of the SkinDex-16 and SkinDEx-29 were so high, only the total scores were used for the
correlation calculations. Significant correlations were noted among anxiety, depressive
symptoms, spirituality, fatigue distress, age and both the SkinDex-29 and SkinDex-16. All
variables with significant correlations with the SkinDex instruments were included in a
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regression analysis. Level of education was significantly correlated with SkinDex-29 but not
with SkinDex-16 therefore, it was omitted from the SkinDex-16 regression analysis.
Independent samples t-tests were conducted for the categorical variables of gender, ethnicity,
and stage of disease. The t-test results demonstrated statistically significant relationships and
these variables were ultimately included in the regression analysis.
The predictor variables were regressed onto the SkinDex-16 and SkinDex-29 to evaluate
for significant relationships. The variables of depressive symptoms, age, and fatigue distress
were shown have significant relationships with the SkinDex-29. It has been shown that as age
increases participants are less likely to report symptoms when compared to a younger
population who has been diagnosed with a very visible skin condition (Gelfand et al, 2004).
Depressive symptoms demonstrated a significant positive relationship with the SkinDex29. These results are not surprising due to the fact that as dermatologic symptoms increase,
the level of depressive symptoms would also increase. Any indication of disease progression in
a patient with a cancer diagnosis would enhance an expectation of an increase in depressive
symptoms. Also, fatigue distress demonstrated a positive correlation with Skin-Dex-29. Fatigue
is a known side effect of cancer and the treatment for cancer and is commonly associated with
depression. As disease progresses, it would be expected that fatigue would increase also.
When fatigue interferes with activities of daily living, or normal activities it causes distress for
the participants. Therefore, the positive correlation between fatigue distress and increased
dermatologic symptoms would be expected. It’s important to note that older patients are
typically retired and have the ability to rest when they feel fatigue. A younger population that
may be responsible for maintaining a job and caring for a family may find the fatigue to be
more distressing.
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In the regression analysis of the predictor variables onto SkinDex-16, the only variable
that demonstrated a significant relationship was fatigue distress. This positive relationship
reveals that as the severity of the dermatologic symptoms increases, fatigue distress increases
as well. Ultimately, when comparing The SkinDex-16 and SkinDex-29 for usefulness, no
difference was identified. The two measurement tools were closely correlated and appeared to
measure the same constructs. Thus, the shorter tool, the Skindex-16, may be more useful in a
busy clinical practice. However, in research it may be more suitable to utilize the Skindex-29 as
it offers more variety in the information obtained.
Implications of the Study
The results of this study have identified significant predictors of QOL and identified
relationships among variables that evaluate the effect of cutaneous symptoms and how they
contribute to the QOL. Some of the measurement instruments utilized in this study were
closely correlated and may have measured some of the same constructs. Factors that may
have influenced the outcome of the study included when patients have their disease staged.
Patients are staged at their initial visit to an oncologist. As they receive treatment for their
disease, their stage of disease improves, thereby improving their quality of life. The initial stage
at diagnosis follows the patient through their treatment trajectory and never changes even if
their clinical stage improves or worsens. These are factors that need to be noted when
evaluating results based on stage of disease. Mean scores were reported, meaning that
although some of the participants experienced little impact of depressive symptoms or anxiety,
there were some participants who were more impacted by these symptoms. Evaluating for
predictors that influence the QOL helps us to better understand the needs of the patients
afflicted with CTCL. The importance of studying the QOL of the CTCL patients lies in the fact
that we as nurses can assist in alleviating some of the symptoms experienced by the patients,
41

thereby improving their QOL. Further study is warranted in developing interventions to assist in
the preservation of QOL.
Limitations of the study include that there was only one researcher to obtain informed
consent and administer the compiled surveys for completion. This may have contributed to
eligible participants not being approached for participation in the study. A significant number of
participants (n=47) had low stage disease, that may not require any specific therapy. There
was an under-representation of participants with advanced stage disease, which likely affected
the results. Most of the participants were white, lending to an under-representation of minority
groups. Due to the number of participants that had stage IIA disease or less, these results may
represent information for patients with low stage disease. It might be expected that results
may be significantly different when these measurement instruments are administered to a
higher population of patients with advanced stage disease (stage IIB and higher).
A strength of the study is that this disease state makes up less than 3% (approximately
1500-3000 patients) of non-Hodgkin lymphoma diagnoses every year, yet 75 participants
agreed to complete the surveys investigating how their disease affects their quality of life. It
was wonderful to have so many willing participants from a rare and under-studied disease
state.
Implications for nursing are that nurses offer a great wealth of knowledge and education
in managing side effects of cancer and its treatment. Patients with skin diseases are at high
risk of infection, especially if they are exhibiting high symptom burden and suffering from
pruritis. Nurses can provide education to patients, colleagues, and students regarding good
skin care, effective management of the side effects of this disease and prevention of infection.
In the clinical setting, education is important to putting the patient at a psychological advantage
when coping with an incurable disease. Providing support both mentally and physically is
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important for providing adequate care for patients with CTCL. The integration of effective
nursing interventions is important in the care of patients with chronic skin conditions and this is
an area where research can be expanded.
Conclusions
In conclusion, the results of this study revealed that stage of disease and the presence
of depressive symptoms influenced the QOL of patients with CTCL. This is expected because
patients with later stage of disease would have a worse QOL. Also, participants with an
increased number of depressive symptoms would have a worse QOL. These findings have been
well established in the literature and are echoed in the results of this study. The significant
influence of depressive symptoms may be alleviated with the implementation of support groups
for patients diagnosed with CTCL. Assessing for these symptoms in the clinical setting may also
identify patients who are more affected. Early identification would allow the healthcare provider
to refer patients experiencing more severe symptoms of depression for further evaluation by a
specialist.
The SkinDex-16 and the SkinDex-29 were evaluated to determine which would be better
suited for use in this population. The SkinDex-16 is shorter and less burdensome for patients to
complete therefore, it is reasonable for this measure to be used in future studies of this
population. Stage of disease also demonstrated a significant relationship with QOL. Evaluating
dermatologic symptoms experienced by patients may be an indication that the disease is
progressing and may need supportive care and medical intervention. Supportive care in the
form of moisturizing creams can be initiated by the nurses in the clinical setting. Promotion of
good skin care will help decrease the desire to itch and maintain the integrity of the skin, which
will decrease the risk of a life threatening infection.

43

Future studies could be conducted to include a larger sample of participants with
advanced (stage IIB and higher) disease. This was designed as an exploratory study. The
patients completed surveys evaluating for anxiety, depressive symptoms, fatigue distress,
spiritual well-being, QOL, and dermatologic symptoms. It is known that some of these
instruments measure similar constructs. It is plausible that multi-colinearity may account for
the lack of significance of anxiety or fatigue distress on QOL. In future studies, it would be
helpful to focus on fewer variables to highlight the influence on QOL in CTCL patients. In
addition, studies to incorporate nursing interventions for skin care and wound care
management would also be beneficial.
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Appendix B: Measurement Instruments
Skindex29
MMChren,1996

DERMATOLOGY SURVEY

This survey concerns the skin condition which has bothered you the most during
the past four weeks.

Date:

Patien.,..t:::ID::-:- - CES-DSCALE
~-:le

1he number for each statement 'N!hiich best describes how often you ·felt or b'~hav:scl this
DURING THE PAST WEEK
Occasionally
Rarely or
. ora
Some or
None of
the Time a Little of
Moderate
Most or All
(Less
the Time
Amount of of the Time
{1-2 days)
Time
than
(5-7 days)
DURING THE PAST WEEK:
(3-4 days)
1 day)
1. I was bothered by things that usually
0
1
2
3
don't bother me.
2. I did not feel like eating; my appetite was
1
0
2
3
poor.
3. I felt that I could not shake off the blues
1
0
2
3
even with he!!>_from my family or friends.
4. I felt that I was just as good as other
1
2
0
3
people.
5. I had trouble keeping my mind on what I
1
2
3
0
was doing.

~r'J -

6. I felt depressed.

0

1

2

3

7. I felt that everything I did was an effort.

0

1

2

3

0

1

2

3

0

1

2

3

·o

1

2

3

11. My sleep was restless.

0

1

2

3

12. I was happy.

0

1

2

3

13. I talked less than usual.

0

1

2

3

14. lfelt lonely.

0

1

2

3

15. People were unfriendly.

0

1

2

3

16. I enjoyed life.

0

1

2

3

1

2

0

1

2

3

0

1

2

3

0

1

2

3

I

I felt hopeful about the future.

9. I thought my life had been a failure.
10. I felt fearful.

:-1Z. 1 hacLccying spells~
--

-

--

1R. I felt sad.
1l:;.

I felt that people disliked me.

20. I could not get "going".

..

_

0

- -
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SELF-EVALUATION QUESTIONNAIRE
STAI Form Y-1

Please provide the following information:
Name. _ _ __ _ _ _ __ _ _ __ _ _ _ _ _Date._ _ _ __ _

s_ _

Age,_ _ __ _ __ _

T_ _

Gender (Circle) M

F

DIRECTIONS:
A number of statements which people have used to describe themselves are given below.
Read each statement and then circle the appropriate number to the right of the statement
to indicate how you feel right now, that is, at this moment. There are no right or wrong
answers. Do not spend too much time on any one statement but give the answer which
seems to describe your present feelings best.

I. I feel calm ...... ...................................................................................................................... ..

2

3

4

2. I feel secure .......................................................................................................................... .

2

3

4

3. I am tense .............................................................................................................................. .

2

3

4

4. I feel strained ........ .. ...............................................................................................................

2

3

4

5. I fee l at ease ........................................................................................................................... I

2

3

4

6. I feel upset ............................................................................................................................ .

2

3

4

7. I am presently worrying over possible misfortunes .......................... ....... ........................... ..

2

3

4

8. I feel satisfied ................ ................ ............... ......................................................................... 1

2

3

4

9. I feel frightened .................................................................................................................... .

2

3

4

I 0. I feel comfortable ................................................................................................................. .

2

3

4

II . I feel se lf-con fid ent ....................................... ............ .......................................................... ..

2

3

4

12. I feel nervous ....................... .......................... ...... ..................................... .................... .........

2

3

4

13. I am jittery .......................................................................................... .................................. .

2

3

4

14. I feel indecisive ............................................................................................ ....................... ..

2

3

4

15. I am re laxed ............................................ .. ....................... .. ........................ .................. ......... .

2

3

4

16. I feel content ......................................................................................................................... .

2

3

4

17. I am worried .......................................................... ............................................................... .

2

3

4

_-= ::=rs::J=teel-eentilsed ....,.................., .............................................................................................. .

2-:--3

19. I feel steady ..................... ...................................................................................................... 1

2

3

4

20. I fee l pleasant ....................................................................................................................... .

2

3

4
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DERMATOLOGY SURVEY

This survey concerns the skin condition which has bothered you the most
during the past week.
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